The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2
复制标题
Abemaciclib 加氟维司群对经内分泌治疗进展的激素受体阳性、ERBB2 阴性乳腺癌总体生存率的影响 — MONARCH 2
作者：
G. Sledge;M. Toi;P. Neven;J. Sohn;Kenichi Inoue;X. Pivot;O. Burdaeva;M. Okera;N. Masuda;P. Kaufman;H. Koh;E. Grischke;P. Conte;Yi Lu;S. Barriga;K. Hurt;Martin Frenzel;S. Johnston;A. Llombart
关键问题：阿贝西利联合福维斯特治疗激素受体(HR)阳性、ERBB2(以前为HER2)阴性的晚期乳腺癌患者是否延长了在以前的内分泌治疗中进展的患者的总体生存时间(OS)？在对669名HR阳性、ERBB2阴性的晚期乳腺癌患者进行的随机、安慰剂对照的MONARCH 2试验中，阿贝西利加福维斯特显著改善了中位OS至46.7个月，而服用安慰剂加福维斯特的患者为37.3个月。这意味着，对于HR阳性、ERBB2阴性、内分泌治疗取得进展的晚期乳腺癌患者，在fulvestrant的基础上加用阿贝西利可使患者的OS延长9.4个月，具有临床意义。
Key Points Question Does treatment with abemaciclib plus fulvestrant prolong the overall survival (OS) of patients with hormone receptor (HR)–positive, ERBB2 (formerly HER2)-negative advanced breast cancer who progressed during prior endocrine therapy? Findings In the randomized, placebo-controlled MONARCH 2 trial of 669 patients with HR-positive, ERBB2-negative advanced breast cancer, abemaciclib plus fulvestrant significantly improved median OS to 46.7 months compared with 37.3 months for patients receiving placebo plus fulvestrant. Meaning The addition of abemaciclib to fulvestrant provided a clinically meaningful median OS benefit of 9.4 months for patients with HR-positive, ERBB2-negative advanced breast cancer that had progressed on endocrine therapy.